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ABSTRACT 
Objective: Solid lipid nanoparticles (SLNs) are at the forefront of the rapidly developing field of nanotechnology with several potential applications 
in drug delivery and research. The aim of this study was to develop and characterize SLNs formulae of Terbinafine HCl (TFH) for topical drug 
delivery applications. 
Methods: SLNs were prepared using the solvent injection technique. Glyceryl Monostearate (GMS) served as the lipid base. Three stabilizers; 
Tween 80, Cremophor RH40, and Poloxamer 188, were used. The effect of stabilizer type and concentration, as well as the lipid concentration, were 
studied, factorial design of 32*21was applied. The prepared SLNs were characterized regarding their particle size, zeta potential, polydispersity 
index (PDI), entrapment efficiency percent (EE %), and physicochemical stability. The selected formulae were subjected to further investigations 
such as morphological studies, in vitro release studies, and Infrared (IR) spectroscopy. They were compared with the marketed cream Lamifen® in 
term of their antifungal activity against Candida albicans. 
Results: Lipid concentration, together with the type and concentration of stabilizer, appeared to be the main cornerstones which affect the 
formation of SLNs. Smaller particle size was observed when increasing the stabilizer concentration and decreasing the lipid concentration. Higher 
EE% was observed when increasing both the stabilizer and the lipid concentrations. Formulae (F6, F12 andF19) were selected as the most suitable 
SLNs with optimum particle size of 480.2±18.89, 458.6±12.45 and 246.7±10.5 nm, respectively as well as the highest EE% of 87.13±0.19, 93.69±0.7 
and 95.06±0.25, respectively. In vitro microbiological screening of their antifungal activity showed significantly larger zones of inhibition of 
diameters 25.9±0.25, 25±0.35 and 24.67±0.36 mm, respectively in comparison with the marketed Lamifen® cream which showed a zone of 
11.2±0.44 mm diameter. 
Conclusion: Applying SLNs containing TFH as topical antifungal preparations may be considered as a very promising option as they show good 
physicochemical characterization with high antifungal activity, which delineates them as a promising dosage form for topical antifungal treatment. 
Keywords: Solid lipid nanoparticles (SLNs), Solvent injection technique, Terbinafine HCl (TFH), Topical drug delivery 




Nanoparticles (NPs) are colloidal drug carriers that range between 1 
to 1000 nanometres (nm) in size with a surrounding interfacial 
layer. NPs have many advantages such as low cost of ingredients, 
ease of preparation as well as being suitable for the preparation of 
hydrophilic and lipophilic drugs. These particles also designed to 
enhance the solubility of poorly soluble drugs [1-3]. NPs may be 
classified according to the type of polymer used in their preparation, 
and, so, they are called polymeric NPs or according to the type of 
lipid used and, hence, called lipid-based NPs. Polymeric NPs are 
colloidal carriers composed of biodegradable macromolecular 
polymers. They increase the therapeutic performance of the poorly 
soluble drug in any route of administration, but unfortunately, they 
suffer from toxic degradation of toxic monomers aggregation [4]. 
Lipid-based colloidal particles have an advantage over polymeric 
systems. They avoid the toxic effect, which may be obtained by the 
polymers used in the polymeric system [5, 6]. 
Lipid NPs can be classified based on the type of the lipid used. Many 
lipids can be used, such as fatty acids, glycerides, and waxes. Some 
important factors must be considered during the selection of the 
lipid phase, such as the solubility of the drug in it, the partitioning of 
the drug between the lipid and aqueous phase, and the lipid 
polymorphism. A solid lipid was selected in the study to produce 
solid lipid nanoparticles (SLNs). Using solid lipids in the formulation 
of NPs has an advantage of reducing drug mobility, decreasing drug 
leakage and also decreases its migration into the interfacial layer. 
SLNs also have the advantage of improving the bioavailability of the 
drug by increasing their dissolution and absorption [4]. 
The main components of SLNs are solid lipid, stabilizers, and active 
ingredients. Co-stabilizers may be used. Stabilizers are another 
name for the surface active agents or the emulsifier. They are the key 
of formation and stabilization of lipid NPs. They help in dispersing 
the lipid in the aqueous phase during the manufacturing process. 
The main action of stabilizer is lowering the surface free energy; 
thus, the surface tension between the two phases will decrease (first 
role). Once the lipid NPs were formed, the stabilizer performs its 
second function of stabilizing its structure (second role) [7]. 
Terbinafine HCl (TFH) is effective in the treatment of different skin 
diseases such as dermatophytosis, candidiasis, seborrhoea 
dermatitis, and onychomycosis. Topical therapy is usually the most 
preferred due to the ease of administration. SLNs possess several 
advantages for the topical route of administrations as they increase 
the penetration of the encapsulated drug into the skin along with the 
avoidance of the first-pass metabolism, the avoidance of side effects 
as allergic reactions, and also targeting the active ingredient to the 
affected areas over the skin [8, 9].  
The aim of this study was to develop and characterize SLNs formulae 
of TFH for topical drug delivery system. 
MATERIALS AND METHODS 
Materials 
Terbinafine HCl (TFH); kindly gifted by Amoun Pharmaceutical 
Company, Egypt. Glyceryl monostearate (GMS); BDH Chemicals, Ltd 
Poole England. Poloxamer 188 and cremophor RH40; FlukaChemie, 
Sigma Aldrich, ChemieGmblt, Switzer land. Ethanol and Tween 80; 
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Adwic, El-Nasr Pharmaceutical Chemical Company, Egypt. All 
chemicals are of analytical grade and used without further purification. 
The fungal strain Candida albicans (strain ATTC 10231) was obtained 
from National Research Center, Cairo, Egypt. Sonicator (type USR3) 
(JulaboLabortechnik, Seelbach, West Germany). Hot plate with a 
magnetic stirrer (Model300HS, Japan). Centrifuge: Sigma, Germany. IR 
Spectrophotometer (IR-470) (Shimadzu, Kyoto, Japan). Transmission 
Electron Microscope (TEM) (JEOL, JEM-2100, Japan). Sensitive Electric 
Balance (Shimadzu, Libror AEG-220, Japan). UV-visible 
spectrophotometer (model 1800, Shimadzu Tokyo, Japan). Zetasizer 
Nano (model ZS3600, Malvern Instruments Ltd., Worcestershire, UK). 
Methodology 
Preparation of SLNs of TFH 
In this study, the solvent injection technique was the method used to 
prepare TFH SLNs. The solid lipid was dissolved in a water-miscible 
solvent (e. g., ethanol, methanol, and acetone) or in a mixture of these 
solvents together. This lipid solvent mixture was injected through an 
injection needle into a stirred aqueous phase with or without a stabilizer. 
The presence of a stabilizer within the aqueous phase helped to produce 
lipid droplets at the site of injection and stabilize SLNs by reducing the 
surface tension between water and solvent [10, 11]. 
TFH (1%) was mixed with glyceryl monostearate (GMS) and then 
dissolved into ethanol. They were heated together to above the 
melting point of the lipid (>55°C). The resulted organic solution was 
injected at once into the aqueous phase (distilled water and the non-
ionic stabilizer). The aqueous phase immediately turned milky, and 
this indicated the formation of lipid NPs suspension. The resulted 
suspension was stirred at 500 rpm for three hours on a magnetic 
stirrer. After that, SLNs suspension was sonicated for 15 min.  
Factorial design 
The factorial design was considered as an efficient statistical tool to 
study the influence of numerous factors concurrently. In addition, it 
was more practical to predict and estimate the interaction between 
selected variables and thus reduced the number of experimental 
runs. Stepwise multivariable regression analysis was also used to 
determine the significant factors. 
Eighteen formulae were prepared and entered in JMP (version 14 
software SAF instate inc., Cary NC), a factorial design program used 
to select the optimized formula. A 32*21full factorial design was used 
to define the optimum conditions regarding the selected factors. The 
design involved two factors, each with three levels and one factor 
with two levels. The two factors with the three levels reflect the 
concentration of GMS (2.5, 5 and 10%) and the stabilizer types 
(Tween 80, Cremophor RH40 and Poloxamer 188) and the one 
factor with the two levels reflect the stabilizer concentration (1 and 
2%) as shown in table 1. 
 
Table 1: Composition of the various formulae of TFH SLNs 
Formula code TFH (mg)  GMS (%) Stabilizer (%) in the aqueous phase 
Tween 80 Cremophor RH40 Poloxamer 188 
F1 100 2.5 1   
F2 100 2.5 2   
F3 100 5 1   
F4 100 5 2   
F5 100 10 1   
F6 100 10 2   
F7 100 2.5  1  
F8 100 2.5  2  
F9 100 5  1  
F10 100 5  2  
F11 100 10  1  
F12 100 10  2  
F13 100 2.5   1 
F14 100 2.5   2 
F15 100 5   1 
F16 100 5   2 
F17 100 10   1 
F18 100 10   2 
 
Table 2: Composition of the optimized formula based on 32*21 factorial design 
Formula code TFH (mg) GMS (%) Stabilizer (%) in the aqueous phase 
Tween 80 Cremophor RH40 Poloxamer 188 
F19 100 6.25 1.5   
 
 
Fig. 1: Composition and characterization of the optimized formula (F19) 
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Fig. 2: Surface plot of the most desirable formula (F19) 
 
Selection of the optimized formula by factorial design 
Applying the desirability function of the used software gave rise to a 
new formula F19 with the following composition: 6.25% GMS and 
1.5% tween 80. This formula was the most optimized formula in the 
model (table 2). Fig. 1 illustrates the composition of the optimized 
formula F19 as well as its expected values of particle size and EE%. 
Physicochemical characterization of TFH SLNs 
Particle size analysis, polydispersity index, and zeta potential 
measurement 
Particle size analysis, polydispersity index (PDI), and zeta potential 
(ZP) were performed for all TFH SLNs formulae using Malvern 
Zetasizer. Prior to measurement, two drops of SLNs suspension were 
diluted in 10 ml of distilled water and sonicated for 10 min. After 
that, 0.1 ml was taken and further diluted in another 10 ml of 
distilled water and sonicated for 10 min. The second diluted sample 
was filled in a transparent sizing cuvette [12, 13, 6]. The PDI value 
gave an indication of the homogeneity of the preparations [14]. All 
measurements were performed in triplicate. 
Determination of the drug entrapment efficiency percent (EE %) 
The EE% gave an indication about the suitability of the drug to be 
formulated in a SLNs system. EE% was determined by the indirect 
method by measuring the concentration of the remaining free drug 
in the aqueous phase, which contained the SLNs dispersion by using 
the centrifugation method at 5000 rpm for 30 min at 25 °C [15]. The 
concentration of the free TFH was measured spectrophotometrically 
at λmax=283 nm [16]. All experiments were run in triplicates. EE % 
was determined using the following equation:  
 
Winitialdrug: was the amount of TFH initially used for the preparation of 
the SLNs,  
Wfree drug in suspension: was the amount of free drug determined in 
the aqueous phase after separation of the NPs [17]. 
Morphology of TFH SLNs 
The morphology of the selected TFH SLNs suspension was observed 
using a transmission electron microscope (TEM). One drop of the 
diluted suspension sample was deposited on a film-coated 200-mesh 
copper grid, stained with one drop of 3% (w/v) aqueous solution of 
phosphotungstic acid and allowed to dry. Any excess fluid was 
removed with filter paper before the examination [18]. 
In vitro drug release study 
One gram of the optimized formulae (equivalent to 10 mg of TFH) 
was placed in cellulose membrane, pore size (0.45 µm), at the 
dissolution vessel of the USP dissolution test apparatus II. The 
dissolution media was 250 ml of phosphate buffer (pH 5.5) 
containing 0.8% tween 80, which was added into the dissolution 
media to maintain the sink conditions. The release study was carried 
out at 37 °C±0.5 [9]. The stirring paddle was rotated at a speed of 50 
rpm [19]. Two ml samples were withdrawn and replaced by 2 ml 
fresh phosphate buffer solution at 5, 10, 15, 30, 60, 90, 120, and 150 
min time intervals. They were spectrophotometrically analyzed for 
TFH at its λmax 283 nm. The blank was prepared according to the 
same procedure by using a plain SLNs suspension. The cumulative 
amount of TFH released was plotted as the function of time, and the 
release rate was calculated from the slope of the straight-line 
portion. Experiments were repeated three times as the results were 
expressed as the mean values±SD. 
Infrared (IR) spectroscopy 
Infrared spectra of physical mixtures of pure TFH with each one of 
the used excipients, namely GMS, Tween 80 and Cremophor40, as 
well as those of the selected optimum formulae, were investigated 
using KBr discs. The IR spectra were obtained in the spectral region 
4000-400 cm-1[20]. 
Microbiological evaluation of the selected SLNs formulae 
The cup-plate technique was used to evaluate the antifungal 
activity of the selected SLNs, as described by Barot et al., and 
Sahoo et al., [21, 22]. The evaluation was carried out against 
Candida albicans ATCC 10231, which obtained from The National 
Research Centre, Cairo, Egypt. The selected formulae and the 
marketed lamifen® cream were prepared at a concentration of 1% 
TFH. Sabouraud’s dextrose agar was used for the evaluation of 
these formulae against Candida albicans. Dextrose agar was 
poured into a sterile petri dish followed with surface inoculation 
of Candida albicans (107CFU/ml). Three wells (7 mm diameter 
hole cut) were made in the middle of the agar petri dish and filled 
with 0.1 ml of the selected SLNs formulae, their plain base and 
lamifen® cream, respectively. The plate was then incubated at 37 
°C for 48 h. The diameter of zone of inhibition was measured in 
mm after incubation, recorded and considered as an indication for 
antifungal activity. This method was done in triplicate and mean 
results were calculated [23-25]. 
Effect of the storage time on stability of the selected formulae  
TFH loaded SLNs optimized formulae were investigated for their 
stability. The samples were stored at controlled ambient 
temperature (25°C) for three and six months. The samples were 
analyzed for their particle size, zeta potential, PDI and EE%. 
Statistical analysis 
All data were expressed as mean±standard deviation (n=3). They 
were subjected to one way ANOVA followed by Tukey Kramer's 
post-test using Instat 3 software. A difference between means was 
considered significant if the P-value was less than or equal to 0.05. 
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RESULTS AND DISCUSSION 
Physicochemical characterization 
The effect of different formulae variables and their interaction was 
studied and statistically analyzed. The results are listed in table 3and 
illustrated in fig. 3. 
Particle size analysis and polydispersity index (PDI) 
Particle size was selected to be one of the dependent variables, and 
the PDI value gave an indication for the homogeneity of the 
preparations. PDI of all the prepared formulae was found to be 
(0.375-1). 
The effect of stabilizer type on the particle size 
The particle size of the prepared SLNs was significantly affected by 
changing the stabilizer type as follows, using poloxamer as stabilizer 
significantly increased the particle size (**p<0.0001) while using any 
of Tween 80 or CremophorRH40 exerted a less significant negative 
effect and decreased the particle size of the SLNs (*p<0.05). The 
SLNs formulae prepared using 1 and 2 % w/w poloxamer 188 (F13 
to F18) showed larger particle size than those prepared using 
1%and 2 % w/w tween 80 and cremophor RH40 (F1 to F12) 
(poloxamer188<tween80<cremophor RH40). This may be due to the 
higher molecular weight of poloxamer 188 compared to tween 80 
and cremophor RH 40 [26]. Vitorino et al.[15] stated that the choice 
of stabilizer is important in the optimization of any NPs formulae. 
The authors added this component contributes not only to control 
the particle size and stability of the dispersions, but also to control 
the crystallization behavior, including polymorphs. 
The effect of stabilizer concentration on the particle size 
Changing the stabilizer concentration from 1 to 2% exerted a 
significant effect on particle size (**p<0.001). The average diameters 
of F7 (1% cremophor RH 40) were 334.80±11.21 nm compared to 
F8 (2% cremophor RH 40) 101±9.45 nm. This was attributed to 
higher stabilizer concentration, which prevented particles’ 
aggregation [27]. These results were in agreement with Tiwari S et 
al., who observed that the stabilizer concentration affects the 
particles’ diameter. They attributed this to the increase in stabilizer 
concentration, which led to the reduction of the interfacial tension 
between the lipid matrix and the aqueous phase resulting in a 
formation of SLNs with smaller particle size [28, 29]. 
The effect of lipid concentration on the particle size 
Changing in lipid concentration exerted a significant main effect on 
the particle size of the prepared SLNs (*p<0.05). The particle size of 
the SLNs formulae prepared using higher lipid concentrations of 
10% (F5, F6, F11, F12, F17, F18) was significantly larger (*P<0.05) 
than their corresponding ones prepared using lower lipid 
concentration of 2.5% (F1, F2, F7, F8, F13, and F14), For example, 
the average diameter of F1 (2.5% GMS) was 243.40±14.73 nm while 
that of F5 (10% GMS) was 694.10±18.82 nm. Moreover, the average 
diameter of F7 (2.5% GMS) was 334.80±11.21 nm compared to F11 
(10% GMS) with 712.30±18.89 nm average diameter. According to 
Shahi and Pathak et. al., the change in particle size may be due to the 
tendency of lipid to coalesce at high lipid concentration [30, 31]. The 
authors added that the lipid concentration was the most important 
factor affecting particles’ diameter. They showed that increasing the 
lipid content of geleol, compritol 888 ATO and percirol ATO from 5 
to 7.5, and 10% resulted in a subsequent increase in particle size 
[32]. 
Two-factor interaction 
The factorial design analysis revealed that there was a significant 
two-factor interaction effect of lipid concentration and type of 
stabilizer on the particle size of the prepared SLNs (*p<0.05). 
 
Table 3: The particle size, polydispersity index, zeta potential and entrapment efficiency of the investigated TFH loaded SLNs 
Formula code *Particle size (nm) *PDI *ZP (mV) *EE% 
F1 243.4±14.73 0.423±0.03 -22.8±0.25 3.30±0.03 
F2 195.5±18.51 0.473±0.04 -19.46±0.29 7.33±0.08 
F3 500.7±12.45 0.56±0.02 -22.33±0.36 14.21±0.05 
F4 470.3±10.15 0.63±0.06 -24.13±0.34 54.68±0.1 
F5 694.1±11.21 0.643±0.05 -22.1±0.26 63.77±0.16 
F6 480.2±18.89 0.533±0.08 -21.60±0.45 87.13±0.19 
F7 334.8±11.45 0.502±0.05 -12.10±0.36 4.69±0.3 
F8 101±9.45 0.357±0.04 -10.50±0.27 19.75±0.5 
F9 478±12.65 0.674±0.06 -24.43±0.35 51.79±0.2 
F10 371.6±11.18 0.579±0.07 -11.90±0.45 65.39±0.16 
F11 712.3±15.18 0.922±0.05 -21.30±0.64 89.63±0.14 
F12 458.6±12.45 0.477±0.07 -21.80±0.39 93.69±0.7 
F13 753±12.16 0.689±0.08 -19.90±0.68 16.73±0.2 
F14 530±14.18 0.995±0.09 -17.40±0.45 34.54±0.05 
F15 1647±17.15 0.662±0.05 -18.30±0.23 61.36±0.18 
F16 1592±18.19 0.674±0.02 -23.20±0.28 66.94±0.14 
F17 2223±15.16 1±0.06 -25.70±0.46 89.59±0.16 
F18 1672±11.89 0.93±0.07 -14.80±0.52 92.57±0.19 
F19 246.7±10.50 0.385±0.07 -21.5±0.64 95.06±0.25 
(*All values are expressed as mean n=3,±SD: standard deviations) 
 
Zeta potential 
Zeta potential, which reflects the electric charge on the particles 
surface, was a useful parameter to predict the physical stability of 
colloidal systems [14, 17, 32]. The zeta potential indicated the 
degree of repulsion between close and similarly charged particles in 
the nanodispersion. The zeta potential values above |8-9 mV| were a 
prerequisite for the stability of the nanoparticles. Zeta potential less 
than or equal |21 mV| were considered as advisable for the 
stabilization of suspensions, since very little or no agglomeration 
takes place, while |30 mV| were indicated to full electrostatic 
stability [33]. 
The results of TFH SLNs zeta potential of different formulae are 
shown in table 3. The values of zeta potential were between-10.50 
mV and-24.43 mV. 
Entrapment efficiency  
EE% was the second dependent variable selected to study the effect 
of different formulation variables and their interactions. The results 
are listed in table 3 and illustrated in fig. 3. 
The effect of lipid concentration on EE % 
The lipid concentration exerted a highly significant positive 
effect on EE% of the prepared SLNs (**p<0.0001). As shown in 
fig. 3, a direct relationship was investigated between lipid 
concentration and EE%. This was attributed either to the 
increase in lipids content, which may increase the space for the 
drug molecules to be entrapped or to the increase in the drug-
lipid solubility, which may also lead to an increase the 
entrapment [12]. These results are in full agreement with (Soma 
Abobakr et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 12, 16-25 
20 
et al., 2013), who studied the effect of increasing GMS on 
Irbesartan loaded SLNs. They proved that increasing 
concentration of GMS increased EE% [20]. 
The effect of stabilizer concentration on EE % 
Changing stabilizer concentration from 1 to 2% exerted a 
significant effect on EE% of the prepared SLNs (*p≤0.05). All the 
SLNs formulae prepared using 2% stabilizer concentrations 
showed higher EE% than their corresponding ones containing 1% 
stabilizer (table 3). This was because increasing the stabilizer 
concentration was found to enhance the solubility of the drug and 
so EE% was increased [26]. 
Effect of Stabilizer type on EE% 
Studying the effect of stabilizer’s type on the EE% showed that 
Tween 80 affected the EE% significantly (*p<0.05), while both 
Cremophor RH40 and Poloxamer188 exerted a non-significant effect 
on it (p values>0.05). This may be due to the difference in chemistry 
of these stabilizers, which may affect the solubility of the drug in 
lipid either by increasing or decreasing it, and this will affect EE%. 
These results of studying the effect of changing both the type and 
concentration of stabilizer are in agreement with Ekambaram and 
Abdul Hasan Sathali,  who reported that increasing the 
concentration of stabilizers from 1% to 2% affected EE% 





Fig. 3: Histogram of particle size, entrapment efficiency, and zeta potential of TFH loaded SLNs, (n= 3±SD) 
 
Selection of the optimized formulae 
After a complete analysis of the factorial design with the previously 
set levels of the selected independent variables and their effect on 
the selected important dependant variable of particle size and EE%, 
the two optimum criteria set were suitable particle size and highest 
EE%. Suitable PDI was also taken into consideration. According to 
these criteria, the three optimum formulae (F6, F12, and F19) were 
selected for further evaluation. 
Morphology of prepared SLN formulae 
Optimized formulae were selected for studying their surface 
morphology as they show suitable particle size with the best EE%. 
The morphology of fresh TFH SLNs was observed using TEM. 
Morphology TEM was shown in fig. 4 for F6, F12, and F19.  
TEM photographs revealed that the particles possessed a 
nanometer-size with spherical uniform shape without aggregation. 
The particle size ranged from 480 to 490 nm for F6, from 455 to 470 
nm for F12 and from 245 to 260 nm for F19. 
In vitro drug release study 
The drug was released from SLNs and diffused through the cellulose 
nitrate membrane into the release medium. Drug release was 
measured by determining the drug concentration in the release 
medium. Fig. 5 illustrates the release profile of TFH from optimized 
SLNs. The cumulative release profiles were constructed up to 150 
min. For assessment and comparison, the release profiles evaluation 
was based on the cumulative drug % release and T50%. A non-
significant difference was recorded when comparing the cumulative 
drug release from the formulae (P ˃ 0.05). The cumulative drug 
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release was 74.58%, 70.56% and 66.91% for formulae F6, F12 and 
F19, respectively. In order to determine the release model, the in 
vitro drug release data were analyzed according to zero order, first 
order, and diffusion-controlled mechanism according to Higuchi 
model. The results revealed that the release of TFH from all the three 
optimized formulae obeyed the Higuchi model of matrix diffusion 
with highest R2values, as shown in table 4. This is in agreement with 
Gardouh et al. who stated that drug release by diffusion involves 
three steps which include penetration of water into system causing 
swelling of matrix followed by the conversion of solid lipid into 
rubbery matrix, and then the diffusion of drug from the swollen 
rubbery matrix takes place [34]. To confirm the release mechanism, 
the data were fitted to the Korsmeyer-Peppas equation to describe 
the drug release mechanism from matrix. It was revealed that the 
three formulae showed non-Fickian diffusion with n values 
0.45<n<0.89. T50% recorded a value of 49.22±1.6, 59.46±0.7and 
61.45±1.3 min for F6, F12 and F19, respectively. They showed a non-
significant difference. (P ˃ 0.05). 
 
 
Fig. 4: Transmission electron microscope photographs of the selected formulae, (n=3±SD) 
 














 R2 R2 R2 R2 n Type of diffusion 
F6 0.942 0.820 0.987 0.811 0.866 non Fickian 
F12 0.859 0.74 0.942 0.877 0.848 non Fickian 
F19 0.937 0.763 0.978 0.0.781 0.814 non Fickian 
 
 
Fig. 5: Cumulative release profiles of TFH loaded SLNs, (n= 3±SD) 
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Infrared (IR) spectroscopy  
FT-IR spectroscopy was used to characterize possible interactions 
between the drug and the used excipients. The interactions between 
them often lead to identifiable changes in the IR profile of the 
formulae. FT-IR spectra of TFH, TFH/Tween 80 physical mixture 
(1:1), TFH/GMS physical mixture (1:1), TFH/Cremophor RH40 
physical mixture (1:1), F6, F12 and F19were shown in fig. (6a, b,c,d, 
e, fand g). TFH had characteristic IR peaks at 3038 (alkenyl C-H 
stretch and/or aromatic C-H stretch), 2970 (alkyl C–H stretch), 
2,225 (alkynyl C≡C stretch), 1,596 (alkenyl C0C stretch), 1,490 
(aromatic C0Cbending) cm−1 [35]. The IR spectrum of the developed 
physical mixtures, as well as the formulae (F6, F12, and F19), 
showed minor differences in the positions of the absorption bands of 
TFH. These indicated the incorporation of the drug in SLNs formulae 
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Fig. 6: FT-IR spectra of TFH (a), TFH/Tween 80 physical mixture (1:1) (b), TFH/GMS physical mixture (1:1) (c), TFH/Cremophor RH40 
physical mixture (1:1) (d), FT-IR spectra of F6 (e), FT-IR spectra of F12 (f) and FT-IR spectra of F19 (g) 
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In vitro microbiology assessment 
This test was used to prove the efficacy of the selected SLNs 
formulae against fungal infection caused by Candida albicans. Fig. 7 
show the diameters of zones of inhibition (mm) caused by the 
selected SLNs formulae, plain base for each formula, and the 
marketed lamifen® cream. The larger the zone of inhibition of 
Candida albicans growth, the higher the release rate of the drug from 
the SLNs and the greater the efficacy of the released drug towards 
killing the Candida albicans. Formulae F6, F12 and F19, showed a 
mean zone of inhibition of 25.9±0.25 mm, 25±0.35 mm and 
24.67±0.36 mm, respectively, which were significantly greater than 
the mean zone of inhibition exhibited by the commercial preparation 
lamifen® cream (11.2±0.44 mm) (*P<0.05). 
 
 
Fig. 7: Microbiological agar plate showing zones of inhibition induced by F6, F12, and F19 formulae, plain formula (control), and the 
marketed product, (n= 3±SD) 
 
Effect of storage time on the stability of the selected formulae  
The optimized SLNs formulae were stored under ambient conditions 
for 3 and 6 mo at 25 °C. They were re-evaluated for their particle 
size and EE%. A slight increase in the particle size diameter (fig. 8) 
and slight decrease of EE% (fig. 9) were observed; both were 
statistically non-significant (P>0.05, paired t-test), proving the 
stability of TFH loaded SLNs. 
 
 
Fig. 8: Effect of storage on the particle size of SLNs after three and six months at 25 °C, (n= 3±SD) 
 
 
Fig. 9: Effect of storage on the EE% of SLNs after three and six months at 25 °C, (n= 3±SD) 
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CONCLUSION 
In this design, it was noted that lipid concentration exerted a 
significant effect on particle size and EE%. The type of stabilizer 
chosen and its concentration also showed a significant effect on the 
studied parameters. The selected optimized formulae of the 
prepared TFH SLNs (F6, F12, and F19) obtained optimum particle 
size with the highest EE%. They showed satisfactory in vitro release 
profiles. In vitro microbiology testing depicted that the zone of 
inhibition of these three formulae was visibly more than that 
observed from the market cream (lamifen® cream). 
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